Edition:
India

Profile: Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

6.11USD
15 Feb 2019
Change (% chg)

$0.26 (+4.44%)
Prev Close
$5.85
Open
$5.89
Day's High
$6.28
Day's Low
$5.89
Volume
51,625
Avg. Vol
26,289
52-wk High
$10.32
52-wk Low
$4.50

Seres Therapeutics, Inc., incorporated on October 18, 2010, is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; non-alcoholic steatohepatitis, and obesity and metabolic syndrome.

As of December 31, 2016, the Company's SER-109, a bacterial spore ecology, consisted of an average of approximately 50 bacterial species derived from healthy donors' fecal matter. SER-109 is designed to prevent further recurrences of CDI in patients suffering from recurrent CDI by restoring the dysbiotic microbiome to a state of health. The Company has completed open label Phase Ib/II clinical studies. SER-109 was generally safe in both the Phase Ib/II and Phase II clinical studies. The Company is developing SER-262 as an Ecobiotic microbiome therapeutic, designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI. SER-262 consists of bacteria that are a subset of the bacterial ecology consisting of SER-109. SER-262 is in Phase I clinical stage.

The Company's SER-287 is under development for the treatment of active mild-to-moderate ulcerative colitis and it has commenced a Phase Ib study in the United States. The Company is designing and developing SER-155, an Ecobiotic microbiome therapeutic that may have activity against Gram-positive and Gram-negative enteric bacterial pathogens. It is designing and developing SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of IBD. SER-301 is in preclinical stage.

Company Address

Seres Therapeutics Inc

200 Sidney St
CAMBRIDGE   MA   02139-4218
P: +1617.9459626
F: +1302.6555049

Company Web Links